These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29783628)

  • 1. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?
    Luce M; Bouchara A; Pastural M; Granjon S; Szelag JC; Laville M; Arkouche W; Fouque D; Soulage CO; Koppe L
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate.
    Miyamoto Y; Iwao Y; Mera K; Watanabe H; Kadowaki D; Ishima Y; Chuang VT; Sato K; Otagiri M; Maruyama T
    Biochem Pharmacol; 2012 Nov; 84(9):1207-14. PubMed ID: 22898098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure omega 3 polyunsaturated fatty acids (EPA, DPA or DHA) are associated with increased plasma levels of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in a short-term study in women.
    Liu G; Gibson RA; Callahan D; Guo XF; Li D; Sinclair AJ
    Food Funct; 2020 Mar; 11(3):2058-2066. PubMed ID: 32142084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat.
    Tsutsumi Y; Deguchi T; Takano M; Takadate A; Lindup WE; Otagiri M
    J Pharmacol Exp Ther; 2002 Nov; 303(2):880-7. PubMed ID: 12388676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
    Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
    Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
    Suzuki Y; Sasamoto Y; Yoshijima C; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Pharm Biomed Anal; 2020 May; 184():113202. PubMed ID: 32114159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMPF does not associate with impaired glucose metabolism in individuals with features of metabolic syndrome.
    Lankinen MA; Hanhineva K; Kolehmainen M; Lehtonen M; Auriola S; Mykkänen H; Poutanen K; Schwab U; Uusitupa M
    PLoS One; 2015; 10(4):e0124379. PubMed ID: 25874636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of furancarboxylic acid, a candidate for uremic toxin, in human serum, hair, and sweat, and analysis of pharmacological actions in vitro.
    Sassa T; Matsuno H; Niwa M; Kozawa O; Takeda N; Niwa T; Kumada T; Uematsu T
    Arch Toxicol; 2000 Feb; 73(12):649-54. PubMed ID: 10741476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals.
    Dai J; Yi J; Zhang S; Chen P; Jin H; Yu X; Zhang X
    J Diabetes Investig; 2019 May; 10(3):793-800. PubMed ID: 30353682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of protein-bound uraemic toxins by haemodialysis.
    Niwa T
    Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.
    Deguchi T; Isozaki K; Yousuke K; Terasaki T; Otagiri M
    J Neurochem; 2006 Feb; 96(4):1051-9. PubMed ID: 16445853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
    Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
    Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of uremic toxin transport by organic anion transporters in the kidney.
    Deguchi T; Kusuhara H; Takadate A; Endou H; Otagiri M; Sugiyama Y
    Kidney Int; 2004 Jan; 65(1):162-74. PubMed ID: 14675047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury.
    André C; Bennis Y; Titeca-Beauport D; Caillard P; Cluet Y; Kamel S; Choukroun G; Maizel J; Liabeuf S; Bodeau S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122234. PubMed ID: 32615535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.